150 related articles for article (PubMed ID: 31816122)
21. Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience.
Tremblay D; Vogel AS; Moshier E; Hoffman R; Kremyanskaya M; Zhou S; Schiano T; Mascarenhas J
Eur J Haematol; 2020 Jan; 104(1):72-73. PubMed ID: 31587352
[No Abstract] [Full Text] [Related]
22. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Cherington C; Slack JL; Leis J; Adams RH; Reeder CB; Mikhael JR; Camoriano J; Noel P; Fauble V; Betcher J; Higgins MS; Gillette-Kent G; Tremblay LD; Peterson ME; Olsen JJ; Tibes R; Mesa RA
Leuk Res; 2012 Sep; 36(9):1147-51. PubMed ID: 22578777
[TBL] [Abstract][Full Text] [Related]
23. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.
Sant'Antonio E; Guglielmelli P; Pieri L; Primignani M; Randi ML; Santarossa C; Rumi E; Cervantes F; Delaini F; Carobbio A; Betti S; Rossi E; Lavi N; Harrison CN; Curto-Garcia N; Gisslinger H; Gisslinger B; Specchia G; Ricco A; Vianelli N; Polverelli N; Koren-Michowitz M; Ruggeri M; Girodon F; Ellis M; Iurlo A; Mannelli F; Mannelli L; Sordi B; Loscocco GG; Cazzola M; De Stefano V; Barbui T; Tefferi A; Vannucchi AM
Am J Hematol; 2020 Feb; 95(2):156-166. PubMed ID: 31721282
[TBL] [Abstract][Full Text] [Related]
24. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
25. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
[TBL] [Abstract][Full Text] [Related]
26. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
Benton CB; Tanaka M; Wilson C; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2015 Apr; 39(4):419-23. PubMed ID: 25687833
[TBL] [Abstract][Full Text] [Related]
27. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
28. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
29. Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.
Reilly CR; Babushok DV; Martin K; Spivak JL; Streiff M; Bahirwani R; Mondschein J; Stein B; Moliterno A; Hexner EO
Am J Hematol; 2017 Sep; 92(9):909-914. PubMed ID: 28543980
[TBL] [Abstract][Full Text] [Related]
30. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
32. Management of advanced phase myeloproliferative neoplasms.
Marcellino B; Mascarenhas J
Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
[TBL] [Abstract][Full Text] [Related]
33. The Genomic Landscape in Philadelphia-Negative Myeloproliferative Neoplasm Patients with Second Cancers.
Hsu CC; Wang YH; Chen YY; Chen YJ; Lu CH; Wu YY; Yang YR; Tsou HY; Li CP; Huang CE; Chen CC
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884495
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France.
Jabagi MJ; Vey N; Goncalves A; Le Tri T; Zureik M; Dray-Spira R
JAMA Netw Open; 2019 Jan; 2(1):e187147. PubMed ID: 30657534
[TBL] [Abstract][Full Text] [Related]
35. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
Wille K; Sadjadian P; Becker T; Kolatzki V; Horstmann A; Fuchs C; Griesshammer M
Ann Hematol; 2019 Jan; 98(1):93-100. PubMed ID: 30155552
[TBL] [Abstract][Full Text] [Related]
36. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
37. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
38. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
Laurenti L; Tarnani M; Nichele I; Ciolli S; Cortelezzi A; Forconi F; Rossi D; Mauro FR; D'Arena G; Del Poeta G; Montanaro M; Morabito F; Musolino C; Callea V; Falchi L; Tedeschi A; Ambrosetti A; Gaidano G; Leone G; Foà R
Am J Hematol; 2011 Dec; 86(12):1007-12. PubMed ID: 21953617
[TBL] [Abstract][Full Text] [Related]
39. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
[TBL] [Abstract][Full Text] [Related]
40. Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.
Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):151-7. PubMed ID: 26564251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
